TETRA BIO-PHARMA WKN: A2ASQ8 ISIN: CA88166Y1007 Kürzel: TBP Forum: Aktien Thema: Hauptdiskussion

Funktioniert die Kopier Funktion in der App nicht mehr?

Mitschnitt des gestiegen WSR live Intervie mit $TBP CEO https://twitter.com/WallStreetRprtr/status/1384545900786184196?s=19

https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2021/Tetra-Bio-Pharma-Announces-Granting-of-U.S.-Patent-for-Treatment-of-Interstitial-Cystitis/default.aspx

https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2021/Tetra-Bio-Pharma-Provides-Update-on-Its-New-Drug-Submission-Application-in-Canada/default.aspx

Wäre mal ein Lichtblick am Horizont

... Having submitted the response within the allowable timeframe allows Tetra to maintain its anticipated launching of REDUVO in the second half of 2021."

OTTAWA, ON / ACCESSWIRE / April 14, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development announce they have advanced the REDUVO soft gel capsules New Drug Submission (NDS) file by responding to a request for more information from Health Canada, as previously announced on March 15, 2021.

https://ceo.ca/@accesswire/fda-provides-positive-feedback-on-tetra-bio-pharmas-311f2

TBPMF : Health Canada gives green light to Tetra Bio's ARDS-003 trial in COVID-19 • 5:04 AM Tetra Bio-Pharma (OTCQB:TBPMF) announces that Health Canada supports the filing of a Clinical Trial Application (CTA) for assessing their novel drug candidate, ARDS-003, in patients with COVID-19. Tetra's trial will be the first worldwide drug which involves the use of an injectable sterile synthetic cannabinoid in patients infected by COVID-19. The proposed study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ascending doses of ARDS-003 in hospitalized COVID-19 patients with pneumonia and at risk of developing acute respiratory distress syndrome. Health Canada acknowledged that Tetra's extensive nonclinical data meet the authority's requirements for a New Molecular Entity and granted the Company the approval for filing a CTA. The authorities also agreed on the proposed study design, target population, and primary and secondary objectives and endpoints of the study in severe COVID-19 patients. The investigational drug is designed to dampen the cytokine release syndrome and will be administered in combination with dexamethasone

https://finance.yahoo.com/news/tetra-bio-pharma-initiates-additional-060000466.html

https://twitter.com/Drpower_2000/status/1372952405520875520?s=19

Short Intrest... https://twitter.com/Habilis15/status/1372973841551622148?s=19

Darauf erstmal 8% runter 😂 alles nicht normal...

Top. Danke Hanni👌

https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2021/Tetra-Bio-Pharma-Receives-Compliant-Rating-on-Inspection-from-Health-Canada/default.aspx

Dann hoffen wir mal auf die Pipeline, denn die eigentliche Meldung ist dünn: The dossier at Health Canada completed the screening phase. To facilitate the product approval, and due to the nature of the data supporting the NDS, Health Canada has recommended an unconventional regulatory pathway and therefore requested additional information to fulfill all requirements of that proposed prescription drug approval pathway. The positive feedback and communication received from Health Canada, which are part of the regular review process, do not increase the expected review timeline. Tetra is working towards submitting the response to Health Canada within the allowable timeframe.